27 March 2018
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Appointment of Dr Adam Hill as Chief Medical Officer and Chief Strategy Officer
Nottingham, UK – 27 March 2018: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces the appointment of Dr Adam Hill MB PhD, to the Company’s Board as Chief Medical Officer and Chief Strategy Officer, commencing on 9 April 2018.
Adam is a dual-qualified Clinician and Engineer, with a career built in industry, academia and practising medicine. During his career, Adam has held Chief Medical Officer and other senior management roles at private and listed companies, supplemented by advisory and government policy appointments.
Most recently, Adam was Chief Medical Officer and later Chief Strategy Officer of McLaren Applied Technologies, where he focused on applying the company’s deep technical expertise to improving health outcomes. Adam developed a Digital Therapeutics strategy and grew a team of experienced professionals across Commercial, Product, Programme, Quality and Technical disciplines to deliver against it. Previously, he was Chief Medical Officer at Sectra AB, the listed medical technology and encryption communications company, and a Management Consultant with PA Consulting.
“Adam’s direct experience of developing and executing global growth strategies within healthcare will be hugely beneficial to Oncimmune as we continue to expand into additional markets with additional products. On behalf of the Board, I would like to take this opportunity to welcome Adam to the Company. We believe he will make a make a significant contribution to further enhancing and delivering on Oncimmune’s strategy.”
Meinhard SchmidtNon-Executive Chairman of Oncimmune
“Oncimmune’s core technology has enormous potential based on its ability to detect cancer four years earlier than other methods using a robust blood test – a liquid biopsy. I look forward to bringing my experience to the Company and working with the team to fully develop this potential as we commercialise the platform globally.”
Adam graduated from Imperial College London as a Medical Doctor, whilst also earning a PhD in Engineering, attending Imperial College Business School, and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers. Adam has built a portfolio of over 100 academic peer-reviewed, policy and popular-media publications. Currently, he is both a Visiting Professor in Global Health Innovation at Imperial College London, and sits on the Advisory Board of Imperial College Health Partners.
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
- Full name and age: Adam Mark Hill, 37 years old
- Current Directorships:
- Past Directorships (within the previous 5 years):
- DON'T HESITATE TO COPE LIMITED (06715614)
- STRENSON MEDICAL LIMITED (07013921)
Dr. Hill does not currently hold any ordinary shares in Oncimmune.
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Giles Balleny, Hugh Kingsmill Moore
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Berenberg (Joint Broker)
Toby Flaux, Charlotte Sutcliffe
+44 (0)20 3207 7800
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
+44 (0)20 3709 5708
Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com